Skip to content

Median effective dose of bupivacaine for spinal anesthesia for cervical cerclage

Median effective dose of bupivacaine for spinal anesthesia for cervical cerclage

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069409
Enrollment
Unknown
Registered
2023-03-15
Start date
2021-07-31
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical incompetence

Interventions

13-16 weeks' gestation group/17-27 weeks' gestation group:Different doses of bupivacaine

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Women in the second trimester (13-27 weeks) who are going to undergo cervical cerclage (Mc-Donald) due to cervical insufficiency; 2. ASA grade I or II; 3. Before starting the activities related to the test, voluntarily sign the informed consent form, fully understand the purpose and significance of the test, and voluntarily abide by the test process.

Exclusion criteria

Exclusion criteria: 1. Contraindications to intraspinal anesthesia; 2. Hypertension, preeclampsia, diabetes and cardiovascular and cerebrovascular diseases were complicated; 3. Multiple pregnancy, difficulty in epidural intubation; 4. Patients with drug allergy or other contraindications; 5. Other situations in which the investigator judged that the subject was not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
anesthesia plane;

Secondary

MeasureTime frame
Nausea, hypotension, bradycardia;

Countries

China

Contacts

Public ContactLihong Zhang

Shengjing Hospital of China Medical University

cbyao@126.com+86 18940255679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026